Persistence of HIV transmission clusters among people who inject drugs

AIDS. 2020 Nov 15;34(14):2037-2044. doi: 10.1097/QAD.0000000000002662.

Abstract

Objective: We investigated the duration of HIV transmission clusters.

Design: Fifty-four individuals newly infected at enrollment in the ALIVE cohort were included, all of whom had sequences at an intake visit (T1) and from a second (T2) and/or a third (T3) follow-up visit, median 2.9 and 5.4 years later, respectively.

Methods: Sequences were generated using the 454 DNA sequencing platform for portions of HIV pol and env (HXB2 positions 2717-3230; 7941-8264). Genetic distances were calculated using tn93 and sequences were clustered over a range of thresholds (1--5%) using HIV-TRACE. Analyses were performed separately for individuals with pol sequences for T1 + T2 (n = 40, 'Set 1') and T1 + T3 (n = 25; 'Set 2'), and env sequences for T1 + T2 (n = 47, 'Set 1'), and T1 + T3 (n = 30; 'Set 2').

Results: For pol, with one exception, a single cluster contained more than 75% of samples at all thresholds, and cluster composition was at least 90% concordant between time points/thresholds. For env, two major clusters (A and B) were observed at T1 and T2/T3, although cluster composition concordance between time points/thresholds was low (<60%) at lower thresholds for both sets 1 and 2. In addition, several individuals were included in clusters at T2/T3, although not at T1.

Conclusion: Caution should be used in applying a single threshold in population studies where seroconversion dates are unknown. However, the retention of some clusters even after 5 + years is evidence for the robustness of the clustering approach in general.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Cluster Analysis
  • Genes, env
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Infections / transmission*
  • HIV-1 / genetics*
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Phylogeny
  • Seroconversion
  • Substance Abuse, Intravenous / complications*
  • env Gene Products, Human Immunodeficiency Virus
  • pol Gene Products, Human Immunodeficiency Virus

Substances

  • HIV pol protein p65
  • env Gene Products, Human Immunodeficiency Virus
  • pol Gene Products, Human Immunodeficiency Virus